ARWR יחס מהיר Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (ARWR) leads the RNA therapeutics segment, developing drugs to block hazardous genes. The immediate liquidity chart confirms the issuer's solvency, where 5.76 reflects the latest metric value. The company incurs high costs to maintain a strict cold chain during drug transportation. Environmental policy is based on standard laboratory solvent control and energy efficiency in offices.

For the long-term investor, the reliability of Arrowhead Pharmaceuticals (ARWR) is determined by its ability to fund the development of RNA drugs using cash and accounts receivable, bypassing low-liquidity inventories. By analyzing the quick ratio, you assess the company's ability to cover obligations with liquid assets, which, given the investment phase of the biotech sector, is critically important for ensuring business sustainability between advance payments from pharma behemoths.